Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Baldwin, the most common co-covered peer. Michael McGarrity appears in 1 tracked Biotech story from February 27, 2026. The tracked stories average 3 original sources each.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Baldwin, the most common co-covered peer. Michael McGarrity appears in 1 tracked Biotech story from February 27, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Michael McGarrity. Shared-story counts are live from our verified record — not editorial picks.
NDA Submission
Planned submission of paltusotine New Drug Application to the FDA.
Phase 3 Initiation
Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
Earnings Call
Management confirms commercial readiness and pipeline acceleration.
PATHFNDR-2 Success
Completion of Phase 3 trial for paltusotine in acromegaly with positive results.
Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
Michael McGarrity is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
